5 Must-Read Analyst Questions From BD's Q4 Earnings Call

Becton, Dickinson and Company’s fourth quarter results were shaped by ongoing portfolio transformation, targeted investments in growth platforms, and the headwind of international tariffs. Management credited strong performance in biologic drug delivery, advanced tissue regeneration, and pharmacy automation, with CEO Thomas E. Polen highlighting "broad-based growth across the markets where we have been doubling down on investments." However, persistent challenges in China and vaccine-related pressures tempered overall top-line momentum, while productivity initiatives and operational discipline supported margin improvement.

Is now the time to buy BDX? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From BD’s Q4 Earnings Call

• Travis Steed (Bank of America) asked about the rationale behind Q2 revenue guidance and the absence of a typical second-half ramp. CEO Thomas E. Polen explained that "Q2 has no ramp versus Q1... no ramp first half to second half either, which is a much better spot."
• Patrick Wood (Morgan Stanley) queried if portfolio changes would hinder normalized mid-single-digit growth. Polen responded that "the fundamentals across the remaining 90% remain very strong," and ongoing investments support future growth.
• Larry Biegelsen (Wells Fargo) sought clarity on headwinds from China, vaccines, and Alaris. Polen confirmed these were "in line with our expectations," with Alaris showing strong competitive momentum and China headwinds expected to moderate after 2026.
• Matt Taylor (Jefferies) asked about the long-term outlook for GLP-1 delivery devices. Polen indicated the franchise remains "on track," nearing the halfway point to the $1 billion target by decade’s end.
• Rick Wise (Stifel) wondered about sources of potential upside to cautious guidance. Polen pointed to high-growth, high-margin segments and commercial process improvements as key areas that could drive better-than-expected results.

Catalysts in Upcoming Quarters

In the coming quarters, our analyst team will be monitoring (1) the pace of commercial adoption for new product launches such as Pyxis Pro, Avatene Flowable, and HemoSphere Stream; (2) execution of manufacturing network consolidation and resulting margin improvements; and (3) stabilization of China and vaccine-related headwinds. Progress on tuck-in acquisitions and continued innovation pipeline acceleration will also be essential signposts for sustained growth.

BD currently trades at $175.43, down from $210.02 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free).

High-Quality Stocks for All Market Conditions

Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.

The names generating the next wave of massive growth are right here in our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.